Anchor Investment Management LLC Sells 5,367 Shares of Johnson & Johnson $JNJ

Key Points

• Anchor Investment Management LLC reduced its stake in Johnson & Johnson by 5.9%, selling 5,367 shares, which now represents 1.3% of its total portfolio.
• Executive Vice President Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock, decreasing her ownership by 24.08%.
• Several institutional investors have adjusted their positions, with 69.55% of Johnson & Johnson shares owned by institutional investors, reflecting significant market interest.

Anchor Investment Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,258 shares of the company's stock after selling 5,367 shares during the period. Johnson & Johnson makes up approximately 1.3% of Anchor Investment Management LLC's portfolio, making the stock its 14th biggest position. Anchor Investment Management LLC's holdings in Johnson & Johnson were worth $14,305,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Hudson Value Partners LLC lifted its stake in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after purchasing an additional 1,022 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Johnson & Johnson by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 323,830 shares of the company's stock valued at $46,827,000 after purchasing an additional 10,387 shares during the last quarter. Minot DeBlois Advisors LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at approximately $927,000. Finally, Measured Risk Portfolios Inc. purchased a new position in Johnson & Johnson in the fourth quarter valued at approximately $1,160,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. Barclays increased their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Guggenheim restated a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Morgan Stanley upped their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $177.12 on Wednesday. The company has a 50-day simple moving average of $169.51 and a two-hundred day simple moving average of $161.02. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The firm has a market cap of $426.57 billion, a price-to-earnings ratio of 18.94, a PEG ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.